Update Your ProfileAcademic Title:
Assistant Professor
Primary Appointment:
Psychiatry
Location:
3rd Floor
Phone (Primary):
410-328-2207
Phone (Secondary):
410-328-8070
Fax:
410-328-2223
Education and Training
2006 B.A., University of Massachusetts Amherst, History
2010 M.D., Boston University School of Medicine, Medicine
2014 Adult Psychiatry Residency, Yale University School of Medicine
Biosketch
I am part of the faculty in the Division of Addiction Research and Treatment at the University of Maryland School of Medicine. Since joining the University of Maryland in 2017, I have worked in different clinical settings within the division of Community Psychiatry and in the Psychiatric Emergency Department. In the Division of Addiction Research and Treatment, I am currently a psychiatrist for the Health and Recovery Practice (HARP), a clinic formed from a partnership with the University of Maryland’s Institute of Human Virology, Faculty Physicians, and Department of Psychiatry that collocates substance use, physical health, mental health, and infectious disease care for patients with substance use disorder. I provide opioid use disorder treatment by telemedicine to patients at the Detention Center located in Queen Anne’s County, Maryland. I provide consultation and psychiatric treatment for a cohort of patients with substance use disorders treated and followed by researchers at the Institute of Human Virology. As a researcher in opioid use disorder, my interests include suicide risk, intentional opioid overdose, psychiatric treatment, and social determinants of health.
Research/Clinical Keywords
Suicide risk, opioid use disorder, substance use disorders, opioid overdose, severe and persistent mental illness, social determinants of health.
Highlighted Publications
Spaderna, M., Rosenthal, E., Kang, S.J., Eyasu, R., Ebah, E., Obgumbadiugha, O., Bijole, P., Cover, A., Davis, A., Zoltick, M., Kottilil, S., Mount, J.,Gannon, C., Stevens, J., Garrett, G., Derenoncourt, M., Liu, T., Horowitz, L., Pao, M., Kattakuzhy, S. (2025). Elevated rate of suicide risk in individuals with opioid use disorder. American Journal on Addictions, 1-10, PMID: 40069095
Spaderna, M., Belcher, A., Smith, H., Fitzsimons, H., Coble, K., Welsh, C., Spicyn, N., Rosenthal, E., Liu, T., Weintraub, E. (2024) If you’ve done one, you’ve done ONE: Implementation outcomes and lessons learned from a novel telemedicine buprenorphine treatment program in six rural detention centers. Health Affairs, Abstract.
Spaderna, M., Kattakuzhy, S., Kang, S.J., George, N., Bijole, P., Ebah, E., Eyasu, R., Ogbumbadiugha, O., Silk, R., Gannon, C., Davis, A., Cover, A., Gayle, B., Narayanan, S., Pao, M., Kottilil, S., Rosenthal, E. (2023). Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use. International Journal of Drug Policy, 111.
Spaderna, M., Bennett, M., Arnold, R., & Weintraub, E. (2021). Case Series of Patients with Opioid Use Disorder and Suicidal Ideation Treated with Buprenorphine. Clinical Practice and Cases in Emergency Medicine, 5(1), 6–10.
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013). Spicing things up: Synthetic cannabinoids. Psychopharmacology, 228(4), 525–540.
Additional Publication Citations
Kelly, D. L., Spaderna, M., Hodzic, V., Nair, S., Kitchen, C., Werkheiser, A. E., Powell, M. M., Liu, F., Coppersmith, G., Chen, S., & Resnik, P. (2020). Blinded Clinical Ratings of Social Media Data are Correlated with In-Person Clinical Ratings in Participants Diagnosed with Either Depression, Schizophrenia, or Healthy Controls. Psychiatry Research, 294, 113496.
Kelly, D. L., Spaderna, M., Hodzic, V., Coppersmith, G., Chen, S., & Resnik, P. (2021). Can language use in social media help in the treatment of severe mental illness? Current Research in Psychiatry, 1(1), 1–4.
Israel, B., Wiprovnik, A.E., Belcher, A.M., Kleinman, M.B., Ramprashad, A., Spaderna, M., Weintraub, E. (2022). Practical Considerations for Treating Comorbid Posttraumatic Stress Disorder in the Addictions Clinic: Approaches to Clinical Care, Leadership, and Alleviating Shame. The Psychiatric Clinics of North America, 45(3), 375-414.
Research Interests
Opioid use disorder, suicide risk, intentional opioid overdose, co-occurring psychiatric and substance use disorders, social determinants of health
Clinical Specialty Details
Severe and persistent mental illness, substance use disorders, dual diagnosis
Awards and Affiliations
American Board of Psychiatry and Neurology
Addiction Medicine, American Board of Preventive Medicine
Grants and Contracts
07/22-06/27 Co-Inv: Principal Investigator: Elana Rosenthal
5-year Programmatic Contract DC Partnership for HIV/AIDS Progress
HHSN272201300022I
Office of AIDS Research
Annual direct costs: 2,478,992.23
Total direct costs: $9,629,106
12/22-6/25 Co-Inv; Principal Investigator: Jay Unick
National Institute of Mental Health
R01 MH128781-01
Bringing Health Home
Annual direct costs: $750,000
Total direct costs: $2,250,000
07/23-02/25 Principal Investigator
Service (CARES) Science to Systems Grant (SSG) program, University of Maryland Center for Addition Research, Education, and Treatment
Improving the Linkage and Retention to Outpatient Psychiatric Care in Individuals with Opioid Use Disorder
Annual direct costs: 25,000
Total direct Costs: $50,000
05/24-05/25 Principal Investigator
Community Engaged Research (CEnR) Grant,
University of Maryland Institute for Clinical and Translational Research
Developing a Screening Tool for Intentional Opioid Overdose
Project ID Number: 305
Total direct costs: $33,852
09/24-09/27 Co-Inv; Principal Investigator: Melanie Bennett, 5% FTE
External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting
National Institute on Alcohol Abuse and Alcoholism
Project ID: 1R34AA032051-01
Annual direct costs: $193,750
Total direct costs: $450,000
9/24-9/27 Co-Inv; Principal Investigator: Sarah Kattakuzhy, 10 % FTE Evaluation of Semaglutide Safety and Tolerability in Adults with Cocaine use Disorder with and without HIV
Office of AIDS Research / NIH Clinical Center
Project ID Number: 75N90024C00036
Total costs: $762,563